Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

AI in Life Sciences Market to Worth USD 69.34 Billion by 2031, at a CAGR of 26.3% – MarketsandMarkets™

globenewswire.com
NVDA NVIDIA is listed as a key player in the AI in Life Sciences market, indicating its role in providing the computing infrastructure for complex life sciences datasets. This suggests strong demand for its AI-related products and services in this growing sector. ILMN Illumina is mentioned as a key player in the AI in Life Sciences market, likely due to its role in genomics, which is a significant data source for AI applications in this field. This positions them to benefit from the market's growth. RRX Recursion Pharmaceuticals, Inc. is listed as a key player in the AI in Life Sciences market, focusing on AI-driven drug discovery. Its involvement indicates a positive outlook tied to the growth of AI applications in pharmaceutical research. MSFT Microsoft Corporation is listed as a key player in the AI in Life Sciences market. Its cloud and AI infrastructure services are crucial for processing complex life sciences data, indicating a positive outlook. PATH PathAI, Inc. is identified as a key player in the AI in Life Sciences market, focusing on AI-powered diagnostics. Its role suggests it will benefit from the increasing adoption of AI in medical diagnostics and healthcare workflows.

AI in Life Sciences Market to Worth USD 69.34 Billion by 2031, at a CAGR of 26.3% – MarketsandMarkets™ Delray Beach, FL , Nov. 04, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global AI in life sciences market to grow from USD 21.58 billion in 2026 to USD 69.34 billion by 2031, at a CAGR of 26.3% during the forecast period. Market growth is fueled by accelerating adoption of AI in drug discovery, clinical research, diagnostics, and precision medicine, along with increasing investments in AI-powered life sciences solutions and the growing availability of real-world and genomic data.

Get PDF Brochure - Market Data & Segmentation: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=45756262

Key Market Highlights

Why This Market Matters

The life sciences industry is increasingly adopting AI to accelerate drug discovery, improve clinical research, strengthen diagnostics, and enable personalized medicine. Traditional drug discovery can take more than a decade and requires substantial investment, while AI helps researchers identify therapeutic targets, analyze complex biological datasets, and predict drug efficacy. Growing use of genomic information, clinical data, and real-world evidence is also supporting more targeted treatment approaches and improved research outcomes. At the same time, AI adoption is creating opportunities to streamline workflows and improve decision-making across pharmaceutical, biotechnology, and healthcare organizations.

Market Overview

The AI in life sciences market is expanding as pharmaceutical companies, biotechnology firms, and contract research organizations integrate AI technologies into research, development, and clinical operations. End-to-end solutions help organizations integrate data, deploy models, and coordinate activities across departments, while software applications support analytics, modeling, and implementation. Cloud-based services enable scalable computing and collaboration across complex datasets, and natural language processing supports the analysis of unstructured information, including clinical notes, scientific literature, and regulatory documents. However, implementation costs, data quality issues, interoperability limitations, and evolving regulatory requirements continue to influence market adoption.

Analyst Perspective

The life sciences industry is moving toward increasingly data-driven and AI-enabled research and healthcare models. Advances in drug discovery, real-world data analytics, and personalized medicine are creating opportunities to improve research productivity and develop more targeted treatments. Regulatory acceptance and institutional adoption of AI are also supporting commercialization, with the US FDA having authorized more than 1,450 AI/ML-enabled medical devices by 2025, according to the supplied source. However, high implementation costs, inconsistent data standards, model reliability concerns, and the need for standardized validation frameworks remain important challenges. Companies that combine scalable AI infrastructure with reliable data integration and specialized life sciences applications are positioned to support the industry's evolving requirements.

Speak to Our Analyst - Get Custom Insights: https://www.marketsandmarkets.com/requestsampleNew.asp?id=45756262

Segment Analysis

By offering, the end-to-end solutions segment held the largest share of the AI in life sciences market, supported by the need for integrated platforms that simplify drug discovery, clinical research, and commercialization. These solutions support data integration, model deployment, and cross-departmental collaboration, reducing the complexity of managing separate tools. Their scalability and operational efficiency make end-to-end platforms an attractive option for organizations seeking to integrate AI across multiple life sciences workflows.

By application, the clinical segment is anticipated to experience rapid growth, driven by increasing use of AI in diagnosis, clinical trial optimization, and patient management. AI technologies support patient recruitment, monitoring, and outcome forecasting, helping improve clinical trial processes and decision-making. The shift toward personalized medicine, combined with growing adoption of AI in medical imaging, disease detection, and clinical workflows, is further supporting the segment's expansion.

By component, the software segment holds the largest market share because AI-based applications support data analytics, model development, and implementation across research and clinical environments. These applications enable complex analytics and automated modeling, while demand for scalable, interoperable, and user-friendly software continues to increase. Software platforms also help organizations manage data-related requirements and support compliance with relevant standards.

By tool, natural language processing (NLP) is expected to experience the fastest growth, driven by increasing demand for tools that can analyze unstructured data, including clinical notes, scientific research papers, and regulatory documents. NLP supports more efficient information processing and decision-making across research and clinical activities. Advances in language models are further expanding applications in literature mining, clinical documentation, and pharmacovigilance.

By deployment mode, cloud-based services hold the largest market share due to their scalability, flexibility, and affordability in managing large and complex datasets. Cloud platforms facilitate remote collaboration, AI model deployment, and integration of multiple data sources. They also support high-performance computing requirements for applications such as genomics and drug discovery, enabling organizations to improve flexibility while managing infrastructure costs.

By end user, the biotechnology segment is predicted to grow faster, supported by its innovation-driven approach and early adoption of emerging technologies. Biotechnology companies use AI for target identification, molecular modeling, and precision medicine applications. Increasing investment and collaboration between biotechnology companies and technology providers are further supporting the adoption of AI across biotechnology research and development.

Regional Analysis

Asia Pacific is experiencing rapid growth in the AI in life sciences market as healthcare organizations increasingly adopt AI-enabled systems and move beyond pilot projects toward broader implementation. The region's expansion is supported by growing institutional adoption, increasing demand for digital healthcare solutions, and the use of AI to improve productivity and access to care. According to the supplied source, IDC data from 2026 indicate that approximately 75% of healthcare organizations in Asia Pacific anticipate increased productivity from AI-powered systems, while the Philips Future Health Index 2025 found that 89% of healthcare professionals in the region believe AI could save lives through early intervention.

Key Industry Trends

Competitive Landscape

The competitive landscape of the AI in life sciences market includes technology providers, genomics companies, AI-driven drug discovery businesses, healthcare data specialists, and AI-powered diagnostics companies. Key players include NVIDIA Corporation (US), Illumina, Inc. (US), Tempus AI, Inc. (US), Recursion Pharmaceuticals, Inc. (US), Dassault Systèmes SE (France), Schrödinger, Inc. (US), Data4Cure, Inc. (US), Microsoft Corporation (US), Insilico Medicine Ltd. (Hong Kong), BenevolentAI Limited (UK), Owkin, Inc. (France), PathAI, Inc. (US), Aidoc Medical Ltd. (Israel), Qure.ai Technologies Pvt. Ltd. (India), Deep Genomics Inc. (Canada), and SOPHiA GENETICS SA (Switzerland). These companies are advancing AI applications in drug discovery, genomics, molecular modeling, diagnostics, and precision medicine, while cloud and computing providers support the infrastructure required to process complex life sciences datasets.

Related Reports

North America AI in Life Science Market

Europe AI in Life Science Market